Is polypharmacy in older adults a hidden epidemic?

What exactly is polypharmacy, and why is it called a hidden epidemic?

Polypharmacy simply means taking multiple medications at once, but there is no single agreed-upon definition. A 2021 review found 143 different definitions in the medical literature, ranging from taking 5 or more drugs to taking any unnecessary medication [5]. This lack of a clear definition is one reason the problem stays hidden — it's hard to measure what you can't define consistently. The same review found that prevalence varies wildly, from just 4% among older adults living independently to over 96.5% in hospitalized patients [5], showing that the problem is massive but often invisible to the public.

The 'hidden' aspect also comes from how polypharmacy develops. It creeps up over years as patients see different specialists, each adding a medication for a specific condition without always checking what the patient is already taking. A 2023 study of hospitalized older adults with COVID-19 found that the number of discharge medications actually increased compared to admission, meaning hospitalization often makes the problem worse [2]. This happens quietly, without a single doctor overseeing the full picture.

What are the actual harms of polypharmacy in older adults?

The harms are serious and well-documented. A 2024 review in the BMJ states that polypharmacy is linked to adverse drug events, cognitive and functional impairment, increased healthcare costs, and higher risks of frailty, falls, hospitalizations, and mortality [3]. Another 2021 review in Nature Aging confirms that polypharmacy is entangled with geriatric syndromes like frailty, falls, and cognitive decline [4]. These aren't just theoretical risks — they translate into real hospital visits. A 2023 study of adults aged 75+ found that over 20% of patients returned to the hospital within 30 days of discharge, regardless of whether they were on opioids, benzodiazepines, both, or neither [1]. This suggests that the overall burden of multiple medications, not just specific drug combinations, contributes to poor outcomes.

The harms are especially pronounced with certain drug classes. The same study found that 15% of older patients were prescribed benzodiazepines alone, and 2% were co-prescribed both opioids and benzodiazepines — a combination that carries serious risks of sedation, falls, and respiratory depression [1]. A 2023 Malaysian study found that the most common potentially inappropriate medications were long-term use of proton pump inhibitors (12.3% of patients) and drugs that increase the risk of postural hypotension (7.4%) [2]. These are drugs often seen as harmless, yet they contribute to falls and fractures in older adults.

Can polypharmacy be reversed, and what actually works?

Yes, polypharmacy can be addressed, and the main strategy is called deprescribing — the planned, supervised process of reducing or stopping medications that are no longer needed or may be causing harm. A 2024 review found that just over half of deprescribing interventions tested in randomized controlled trials performed better than usual care in at least one primary outcome [3]. These interventions typically involve medication reviews in primary care, shared decision-making with patients, training for healthcare professionals, and patient education materials [3]. The same review notes that most studies were short (12 months or less), so long-term benefits are still being studied.

A key tool for identifying problematic medications is the Beers Criteria and STOPP criteria, which list potentially inappropriate medications for older adults. A 2023 study found that using these criteria, 32.7% of hospitalized older COVID-19 patients had at least one potentially inappropriate medication [2]. The study also found that a history of hospital admission in the past year more than doubled the odds of being on an inappropriate medication (odds ratio 2.27) [2], suggesting that hospitalizations are a critical opportunity for medication review. The authors emphasize that clinical pharmacists conducting medication reviews can identify and reduce these risky drugs [2]. Looking forward, researchers are exploring high-tech approaches like multiomics profiling to better predict which patients are at highest risk from polypharmacy [4].

About These Sources

This answer is built on 5 peer-reviewed studies — published from 2021 to 2024, 1 from 2024 or later, 3 in Q1 journals, collectively cited 562 times — selected as the most relevant from 5 studies that passed quality screening, drawn from 58 papers retrieved from a database of over 500 million.

Sources used in this answer

Related research questions